Difference between revisions of "MNX1-AS1"
(Created page with "==Annotated Information== ===Approved Symbol=== MNX1-AS1 ===Approved Name=== MNX1 antisense RNA 1 (head to head) ===Previous Symbols=== _ ===Synonyms=== "CCAT5, LOC645249" ===...") |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| − | === | + | ===Name=== |
| − | MNX1-AS1 | + | MNX1-AS1:MNX1 antisense RNA 1 (head to head)<ref name="ref1" /> |
| − | + | ||
| − | MNX1 antisense RNA 1 (head to head) | + | CCAT5, LOC645249 |
| − | === | + | |
| − | + | ===Characteristics=== | |
| − | === | + | MNX1-AS1 (MNX1 antisense RNA1) is an lncRNA located on chromosome 7 (7q36.3) that makes transcripts from the antisense strand near the 5' end of the protein-coding gene <ref name="ref1" /> |
| − | " | + | |
| − | === | + | ===Function=== |
| − | + | MNX1-AS1 functions as an oncogene in ovarian cancer <ref name="ref2" />. Higher expression of lncRNA MNX1-AS1 is closely associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in ovarian cancer patients <ref name="ref2" />. Downregulation of MNX1-AS1 will suppress cell proliferation, colony formation, cell migration ability, induce cell cycle arrest at the G0/G1 phase, and promote apoptosis. Furthermore, MNX1-AS1 knockdown will altere the protein expressions of CDK4, cyclin D, Bax, and Bcl-2 <ref name="ref2" />. | |
| − | === | + | |
| − | + | ===Diseases=== | |
| − | === | + | ovarian cancer <ref name="ref2" /> |
| − | + | ||
| − | === | + | ===Expression=== |
| − | + | In ovarian cancer tissue MNX1-AS1 levels are significantly upregulated nearly fourfold the normal tissue <ref name="ref2" />. | |
| − | === | + | |
| − | + | ===Sequence=== | |
| + | >NR_038835.1 Homo sapiens MNX1 antisense RNA 1 (head to head) (MNX1-AS1), long non-coding RNA | ||
| + | <dnaseq>GGGGACACCAACGGGGAGTGGATACTCCGAGGCTCAACCTGGGGCCTCTGCCCGCCCTCCCCTGGGTGCG | ||
| + | GAGCCGGACGGCGGGCACTGGCAACCCCCGGGCCCCTGGAGAGCCCCGCGGCGGCCCAAGACCCGCTCCC | ||
| + | GAGACACGTGGGCCCCTCCGGACTTGGTTGGTCCCTGGAGCCAGCTGCGCGCGTCCTCTCCGGCCTCCTT | ||
| + | GTCGGCGCTGGAGTGGGTCCACGTCTGCCTTGCGGAGCGCGGTGGTTCCACGCTCCTGAGCGCCCACGCT | ||
| + | GCGCAGACCTGGCCGCTCTGCGAGGCGACGGCAGCGCACTGAAGACCGTGGTGTTTCCCAAGCCCTCCCT | ||
| + | GCTCTCGGGCCTCCAGGGCGCAGCAGGGGAGGGTTTTGTCCCCGTGGCCAAAGCTCTGCAGGTCGAACCT | ||
| + | TATCTGCTATGGGAAGGCCCCGCATTTTCAGATTCACGCAGGGCCCTCTGCAGACTGTTGGCAGAAAAAA | ||
| + | GGTAGCCACCAAACACATGCATAAGCTGGACTTTTCCCAGAATGCTGCAGCAGAACTACCCTCCAGATAG | ||
| + | ACACTAGCCTGCGGGCCACAGTGCTACGTGAGTCTTGCAAAGAGGAGATCTTTATGGCGAGGCTGAGAGC | ||
| + | ACTGCCTGCATGCTTTACCAGAGCCCAGCCTCCAGCCTCCACGGAAAATGTGTTTTGGAATCAACACTCT | ||
| + | TTGCAAAGGCTCCACACTGCTTTCTGGTAGCATTGGCCTGGGCGCCCAGGCACTCCTTTAGAACCCACCT | ||
| + | GTTCCCCCCACCCACCCTAGTGGGAGGAGGAGAGGGTTACACTGACAGATACCGGCAGCTCTGCAACCCG | ||
| + | GGAACAACGCAGACAACATACAACTCGACAGAGTCACAGAAGGTGGCGTCCATCGCGCCTGGATGGTGAC | ||
| + | TACTGCCCTGCGGGCTGCTGGGTGGGTGAAACACACAGGGAAGAAGCACAAATACACACACAGATGTGGC | ||
| + | TCAGGGAAAAAA</dnaseq> | ||
| + | |||
| + | |||
| + | ==Labs working on this lncRNA== | ||
| + | *Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.<ref name="ref1" /> | ||
| + | *Department of Obstetrics and Gynaecology, Qilu Hospital of Shandong University , Jinan, China .<ref name="ref2" /> | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> | ||
| + | Goyal A, Myacheva K, Groß M, Klingenberg M, Duran Arqué B, Diederichs S. | ||
| + | Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic | ||
| + | Acids Res. 2017 Feb 17;45(3):e12. | ||
| + | </ref> | ||
| + | <ref name="ref2"> | ||
| + | Lv Y, Li H, Li F, Liu P, Zhao X. Long Noncoding RNA MNX1-AS1 Knockdown | ||
| + | Inhibits Cell Proliferation and Migration in Ovarian Cancer. Cancer Biother | ||
| + | Radiopharm. 2017 Apr;32(3):91-99. | ||
| + | </ref> | ||
| + | </references> | ||
Latest revision as of 02:51, 31 July 2017
Contents
Annotated Information
Name
MNX1-AS1:MNX1 antisense RNA 1 (head to head)[1]
CCAT5, LOC645249
Characteristics
MNX1-AS1 (MNX1 antisense RNA1) is an lncRNA located on chromosome 7 (7q36.3) that makes transcripts from the antisense strand near the 5' end of the protein-coding gene [1]
Function
MNX1-AS1 functions as an oncogene in ovarian cancer [2]. Higher expression of lncRNA MNX1-AS1 is closely associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in ovarian cancer patients [2]. Downregulation of MNX1-AS1 will suppress cell proliferation, colony formation, cell migration ability, induce cell cycle arrest at the G0/G1 phase, and promote apoptosis. Furthermore, MNX1-AS1 knockdown will altere the protein expressions of CDK4, cyclin D, Bax, and Bcl-2 [2].
Diseases
ovarian cancer [2]
Expression
In ovarian cancer tissue MNX1-AS1 levels are significantly upregulated nearly fourfold the normal tissue [2].
Sequence
>NR_038835.1 Homo sapiens MNX1 antisense RNA 1 (head to head) (MNX1-AS1), long non-coding RNA
000001 GGGGACACCA ACGGGGAGTG GATACTCCGA GGCTCAACCT GGGGCCTCTG CCCGCCCTCC CCTGGGTGCG GAGCCGGACG 000080
000081 GCGGGCACTG GCAACCCCCG GGCCCCTGGA GAGCCCCGCG GCGGCCCAAG ACCCGCTCCC GAGACACGTG GGCCCCTCCG 000160
000161 GACTTGGTTG GTCCCTGGAG CCAGCTGCGC GCGTCCTCTC CGGCCTCCTT GTCGGCGCTG GAGTGGGTCC ACGTCTGCCT 000240
000241 TGCGGAGCGC GGTGGTTCCA CGCTCCTGAG CGCCCACGCT GCGCAGACCT GGCCGCTCTG CGAGGCGACG GCAGCGCACT 000320
000321 GAAGACCGTG GTGTTTCCCA AGCCCTCCCT GCTCTCGGGC CTCCAGGGCG CAGCAGGGGA GGGTTTTGTC CCCGTGGCCA 000400
000401 AAGCTCTGCA GGTCGAACCT TATCTGCTAT GGGAAGGCCC CGCATTTTCA GATTCACGCA GGGCCCTCTG CAGACTGTTG 000480
000481 GCAGAAAAAA GGTAGCCACC AAACACATGC ATAAGCTGGA CTTTTCCCAG AATGCTGCAG CAGAACTACC CTCCAGATAG 000560
000561 ACACTAGCCT GCGGGCCACA GTGCTACGTG AGTCTTGCAA AGAGGAGATC TTTATGGCGA GGCTGAGAGC ACTGCCTGCA 000640
000641 TGCTTTACCA GAGCCCAGCC TCCAGCCTCC ACGGAAAATG TGTTTTGGAA TCAACACTCT TTGCAAAGGC TCCACACTGC 000720
000721 TTTCTGGTAG CATTGGCCTG GGCGCCCAGG CACTCCTTTA GAACCCACCT GTTCCCCCCA CCCACCCTAG TGGGAGGAGG 000800
000801 AGAGGGTTAC ACTGACAGAT ACCGGCAGCT CTGCAACCCG GGAACAACGC AGACAACATA CAACTCGACA GAGTCACAGA 000880
000881 AGGTGGCGTC CATCGCGCCT GGATGGTGAC TACTGCCCTG CGGGCTGCTG GGTGGGTGAA ACACACAGGG AAGAAGCACA 000960
000961 AATACACACA CAGATGTGGC TCAGGGAAAA AA
000081 GCGGGCACTG GCAACCCCCG GGCCCCTGGA GAGCCCCGCG GCGGCCCAAG ACCCGCTCCC GAGACACGTG GGCCCCTCCG 000160
000161 GACTTGGTTG GTCCCTGGAG CCAGCTGCGC GCGTCCTCTC CGGCCTCCTT GTCGGCGCTG GAGTGGGTCC ACGTCTGCCT 000240
000241 TGCGGAGCGC GGTGGTTCCA CGCTCCTGAG CGCCCACGCT GCGCAGACCT GGCCGCTCTG CGAGGCGACG GCAGCGCACT 000320
000321 GAAGACCGTG GTGTTTCCCA AGCCCTCCCT GCTCTCGGGC CTCCAGGGCG CAGCAGGGGA GGGTTTTGTC CCCGTGGCCA 000400
000401 AAGCTCTGCA GGTCGAACCT TATCTGCTAT GGGAAGGCCC CGCATTTTCA GATTCACGCA GGGCCCTCTG CAGACTGTTG 000480
000481 GCAGAAAAAA GGTAGCCACC AAACACATGC ATAAGCTGGA CTTTTCCCAG AATGCTGCAG CAGAACTACC CTCCAGATAG 000560
000561 ACACTAGCCT GCGGGCCACA GTGCTACGTG AGTCTTGCAA AGAGGAGATC TTTATGGCGA GGCTGAGAGC ACTGCCTGCA 000640
000641 TGCTTTACCA GAGCCCAGCC TCCAGCCTCC ACGGAAAATG TGTTTTGGAA TCAACACTCT TTGCAAAGGC TCCACACTGC 000720
000721 TTTCTGGTAG CATTGGCCTG GGCGCCCAGG CACTCCTTTA GAACCCACCT GTTCCCCCCA CCCACCCTAG TGGGAGGAGG 000800
000801 AGAGGGTTAC ACTGACAGAT ACCGGCAGCT CTGCAACCCG GGAACAACGC AGACAACATA CAACTCGACA GAGTCACAGA 000880
000881 AGGTGGCGTC CATCGCGCCT GGATGGTGAC TACTGCCCTG CGGGCTGCTG GGTGGGTGAA ACACACAGGG AAGAAGCACA 000960
000961 AATACACACA CAGATGTGGC TCAGGGAAAA AA
Labs working on this lncRNA
- Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.[1]
- Department of Obstetrics and Gynaecology, Qilu Hospital of Shandong University , Jinan, China .[2]
References
- ↑ 1.0 1.1 1.2 Goyal A, Myacheva K, Groß M, Klingenberg M, Duran Arqué B, Diederichs S. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res. 2017 Feb 17;45(3):e12.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Lv Y, Li H, Li F, Liu P, Zhao X. Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer. Cancer Biother Radiopharm. 2017 Apr;32(3):91-99.
